Back to Clinical Trials

Brief Title: Monotherapy or Combination Therapies in Neoadjuvant Urothelial Carcinoma

An Open-Label, Randomized, Phase 2, Umbrella Study to Investigate the Biological Rational of Various Neoadjuvant Therapies for Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Cisplatin-Ineligible or Refuse Cisplatin Therapy and Undergoing Radical Cystectomy


  • Org Study ID: INCB 24360-901
  • Secondary ID: N/A
  • NCT ID: NCT04586244
  • Sponsor: Incyte Corporation


This is a multicenter, open-label, randomized, Phase 2 umbrella study of various neoadjuvant treatment combinations in participants who have muscle-invasive urothelial carcinoma of the bladder and are cisplatin-ineligible or refusing cisplatin therapy and awaiting radical cystectomy.


Participants will be stratified based on Programmed cell Death-Ligand 1 (PD-L1) Combined Positive Score ( CPS) < 10 and PD-L1 CPS ≥ 10.

  • Overall Status
  • Start Date
    January 14, 2022
  • Phase
    Phase 2
  • Study Type


Primary Outcome 1 - Measure:

Primary Outcome 1 - Timeframe: N/A


  • Urothelial Carcinoma


Inclusion Criteria:
* Histologically confirmed transitional cell urothelial carcinoma. Participants with mixed histologies are required to have a dominant (ie, 50% at least) transitional cell pattern.

- * Clinical stage T2-T3b, N0, M0 muscle invasive urothelial carcinoma by CT (or MRI) (Stage II-IIIA per AJCC 2018)

- * Refuse cisplatin therapy (does not apply in France) or are ineligible for cisplatin therapy per modified Galsky criteria with exclusion of Eastern Cooperative Oncology Group( ECOG) PS 2 participants

- * Eligible for radical cystectomy

- * Eastern Cooperative Oncology Group (ECOG) Performance Status( PS) 0 or 1.

- * Pretreatment tumor biopsy must be a tumor block or 20 unstained slides from biopsy of primary tumor containing at least 20% tumor.

- * Willingness to avoid pregnancy or fathering children from screening through 100 days in the US and 190 days in Europe after the last dose of study drug
Exclusion Criteria:
* Participation in any other study in which receipt of an investigational study drug or device occurred within 28 days or 5 half-lives (whichever is longer) before first dose.

- * Previously received systemic therapy for bladder cancer or received prior treatment with checkpoint inhibitor agents (such as anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-CTLA-4).

- * Evidence of measurable nodal or metastatic disease.

- * Concurrent anticancer therapy.

- * Has had major surgery within 4 weeks before enrollment (C1D1).

- * Has had known additional malignancy other than muscle-invasive Urothelial Bladder Cancer ( miUBC) that is progressing or requires active treatment, along with some protocol exceptions, or history of other malignancy within 2 years of study entry, with some predefined-protocol exceptions.

- * Has active autoimmune disease requiring systemic immunosuppression with corticosteroids (> 10 mg daily doses of prednisone or equivalent) or immunosuppressive drugs within 2 years of Day 1 of study treatment.

- * Participants with laboratory values outside of protocol defined ranges.

- * Active autoimmune disease requiring systemic immunosuppression in excess of physiologic maintenance doses of corticosteroids (> 10 mg/day of prednisone or equivalent).

- * Has a known active hepatitis B (defined as HBsAg and total anti-HBc positive results) or hepatitis C (HCV Ab positive result and HCV RNA >LLoD) or HIV,HBV, HCV or hepatitis virus coinfection.

- * Participants with HIV+ disease along with protocol defined exceptions that don't have undetectable viral load along with other protocol exceptions.

- * Has known carcinomatous meningitis.

- * Active infection requiring systemic antibiotics ≤ 14 days from first dose of study drug.

- * Participants with known or suspected active COVID-19 infection.

- * Use of probiotics within 28 days from first dose of study drug.

- * Current use of prohibited medication as per protocol.

- * Has not recovered to ≤ Grade 1 from toxic effects of previous therapy and/or complications from previous surgical intervention.

- * History or presence of an abnormal ECG that, in the investigator's opinion, is clinically meaningful. A screening QTcF interval > 450 milliseconds is excluded.

- * History of a gastrointestinal condition (eg, inflammatory bowel disease, Crohn's disease, ulcerative colitis) that may affect oral drug absorption.

- * Has received a live vaccine within 30days of planned start of study therapy

- * Participants with impaired cardiac function or clinically significant cardiac disease

- * Prior allogenic tissue/solid organ transplant

- * Evidence of interstitial lung disease or active, noninfectious pneumonitis.

- * Has known hypersensitivity to any of the study drugs, excipients, including mannitol or another monoclonal antibody which cannot be controlled with standard measures (eg, antihistamines and corticosteroids).

- * Any ≥ Grade 2 immune-related toxicity while receiving prior immunotherapy.

- * History of serotonin syndrome after receiving 1 or more serotonergic drugs.

- * Concomitant use of medications that are known to be substrates of CYP1A2, CYP2C8, or CYP2C19 with narrow therapeutic window are prohibited (see Section 6.6.3).

- * Patients who are receiving or required to receive medications that are known to be UGT1A9 inhibitors (see Section 6.6.3).

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No


Name: Diane Hershock, MD

Role: Study Director

Affiliation: Incyte Corporation

Overall Contact

Name: N/A

Phone: N/A

Email: N/A


Facility Status Contact